Nilkamal Ltd: Intrinsic Value & Share Price Analysis

Last Updated: December 20, 2025, 4:37 pm

All Competitor Stocks of Nilkamal Ltd

Last Updated: August 1, 2025, 4:20 pm

Below is a detailed analysis of the quarterly data for Nilkamal Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 883.00 Cr.. The value appears to be declining and may need further review. It has decreased from 894.00 Cr. (Mar 2025) to 883.00 Cr., marking a decrease of 11.00 Cr..
• For Expenses, as of Jun 2025, the value is 825.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 809.00 Cr. (Mar 2025) to 825.00 Cr., marking an increase of 16.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 85.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 27.00 Cr..
• For OPM %, as of Jun 2025, the value is 7.00%. The value appears to be declining and may need further review. It has decreased from 10.00% (Mar 2025) to 7.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 3.00 Cr..
• For Interest, as of Jun 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
• For Depreciation, as of Jun 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 26.00 Cr..
• For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 22.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 19.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 10.21. The value appears to be declining and may need further review. It has decreased from 22.87 (Mar 2025) to 10.21, marking a decrease of 12.66.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Last Updated: December 15, 2025, 4:54 am

Last Updated: September 5, 2025, 11:45 am

Last Updated: December 4, 2025, 1:43 am

Below is a detailed analysis of the balance sheet data for Nilkamal Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,492.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,472.00 Cr. (Mar 2025) to 1,492.00 Cr., marking an increase of 20.00 Cr..
• For Borrowings, as of Sep 2025, the value is 539.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 531.00 Cr. (Mar 2025) to 539.00 Cr., marking an increase of 8.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 505.00 Cr.. The value appears to be improving (decreasing). It has decreased from 527.00 Cr. (Mar 2025) to 505.00 Cr., marking a decrease of 22.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 2,552.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,544.00 Cr. (Mar 2025) to 2,552.00 Cr., marking an increase of 8.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 978.00 Cr.. The value appears strong and on an upward trend. It has increased from 936.00 Cr. (Mar 2025) to 978.00 Cr., marking an increase of 42.00 Cr..
• For CWIP, as of Sep 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Mar 2025) to 56.00 Cr., marking a decrease of 19.00 Cr..
• For Investments, as of Sep 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 4.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,466.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,487.00 Cr. (Mar 2025) to 1,466.00 Cr., marking a decrease of 21.00 Cr..
• For Total Assets, as of Sep 2025, the value is 2,552.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,544.00 Cr. (Mar 2025) to 2,552.00 Cr., marking an increase of 8.00 Cr..

Notably, the Reserves (1,492.00 Cr.) exceed the Borrowings (539.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

After reviewing the key financial ratios for Nilkamal Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 71.32. This value is within the healthy range. It has decreased from 81.82 (Mar 24) to 71.32, marking a decrease of 10.50.
• For Diluted EPS (Rs.), as of Mar 25, the value is 71.32. This value is within the healthy range. It has decreased from 81.82 (Mar 24) to 71.32, marking a decrease of 10.50.
• For Cash EPS (Rs.), as of Mar 25, the value is 146.95. This value is within the healthy range. It has decreased from 153.16 (Mar 24) to 146.95, marking a decrease of 6.21.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 996.61. It has increased from 945.46 (Mar 24) to 996.61, marking an increase of 51.15.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 996.61. It has increased from 945.46 (Mar 24) to 996.61, marking an increase of 51.15.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2,219.96. It has increased from 2,141.95 (Mar 24) to 2,219.96, marking an increase of 78.01.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 197.04. This value is within the healthy range. It has decreased from 203.54 (Mar 24) to 197.04, marking a decrease of 6.50.
• For PBIT / Share (Rs.), as of Mar 25, the value is 116.55. This value is within the healthy range. It has decreased from 126.20 (Mar 24) to 116.55, marking a decrease of 9.65.
• For PBT / Share (Rs.), as of Mar 25, the value is 89.22. This value is within the healthy range. It has decreased from 101.44 (Mar 24) to 89.22, marking a decrease of 12.22.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 66.45. This value is within the healthy range. It has decreased from 75.82 (Mar 24) to 66.45, marking a decrease of 9.37.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 71.32. This value is within the healthy range. It has decreased from 81.92 (Mar 24) to 71.32, marking a decrease of 10.60.
• For PBDIT Margin (%), as of Mar 25, the value is 8.87. This value is below the healthy minimum of 10. It has decreased from 9.50 (Mar 24) to 8.87, marking a decrease of 0.63.
• For PBIT Margin (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 5.24, marking a decrease of 0.65.
• For PBT Margin (%), as of Mar 25, the value is 4.01. This value is below the healthy minimum of 10. It has decreased from 4.73 (Mar 24) to 4.01, marking a decrease of 0.72.
• For Net Profit Margin (%), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 5. It has decreased from 3.53 (Mar 24) to 2.99, marking a decrease of 0.54.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 8. It has decreased from 3.82 (Mar 24) to 3.21, marking a decrease of 0.61.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.15. This value is below the healthy minimum of 15. It has decreased from 8.67 (Mar 24) to 7.15, marking a decrease of 1.52.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.00. This value is below the healthy minimum of 10. It has decreased from 10.65 (Mar 24) to 9.00, marking a decrease of 1.65.
• For Return On Assets (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 5. It has decreased from 5.50 (Mar 24) to 4.18, marking a decrease of 1.32.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has increased from 0.08 (Mar 24) to 0.13, marking an increase of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.25. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.25, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.39. It has decreased from 1.49 (Mar 24) to 1.39, marking a decrease of 0.10.
• For Current Ratio (X), as of Mar 25, the value is 2.30. This value is within the healthy range. It has decreased from 2.79 (Mar 24) to 2.30, marking a decrease of 0.49.
• For Quick Ratio (X), as of Mar 25, the value is 1.17. This value is within the healthy range. It has decreased from 1.48 (Mar 24) to 1.17, marking a decrease of 0.31.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.16. This value is within the healthy range. It has increased from 2.09 (Mar 24) to 5.16, marking an increase of 3.07.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 28.04. This value is within the healthy range. It has increased from 24.41 (Mar 24) to 28.04, marking an increase of 3.63.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.17. This value is below the healthy minimum of 20. It has increased from 12.55 (Mar 24) to 13.17, marking an increase of 0.62.
• For Earning Retention Ratio (%), as of Mar 25, the value is 71.96. This value exceeds the healthy maximum of 70. It has decreased from 75.59 (Mar 24) to 71.96, marking a decrease of 3.63.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.83. This value exceeds the healthy maximum of 70. It has decreased from 87.45 (Mar 24) to 86.83, marking a decrease of 0.62.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 7.21. This value is within the healthy range. It has decreased from 8.22 (Mar 24) to 7.21, marking a decrease of 1.01.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.43. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 3.43, marking a decrease of 0.63.
• For Enterprise Value (Cr.), as of Mar 25, the value is 2,530.87. It has decreased from 2,710.03 (Mar 24) to 2,530.87, marking a decrease of 179.16.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 0.84 (Mar 24) to 0.76, marking a decrease of 0.08.
• For EV / EBITDA (X), as of Mar 25, the value is 8.61. This value is within the healthy range. It has decreased from 8.92 (Mar 24) to 8.61, marking a decrease of 0.31.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.79 (Mar 24) to 0.69, marking a decrease of 0.10.
• For Retention Ratios (%), as of Mar 25, the value is 71.95. This value exceeds the healthy maximum of 70. It has decreased from 75.58 (Mar 24) to 71.95, marking a decrease of 3.63.
• For Price / BV (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.54, marking a decrease of 0.27.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.79 (Mar 24) to 0.69, marking a decrease of 0.10.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks